June 8, 2016 8:26pm

… Which suggests to me - weakness?

Pre-market indications – 4 hits and 0 miss

 

Do you care what happened today, you should … because it has implications to Thursday's sector activity?  

 

 

There are two things that investors need - interpretation of news and translation of related market metrics concerning the stem, cell and gene therapy and regenerative medicine sector to substantiate share pricing.

 

 

U.S. stocks closed higher Wednesday, as the Dow and S&P neared their 52-week intraday highs touched last summer. The Dow closed above the psychologically key 18,000 level for the first time since April 27. The NASDAQ closed up.

The NASDAQ closed UP +12.89 or +0.26% to 4,974.64 and the DOW closed UP +65.77 or +0.37% to 18,005.05.

 

 

A day in the life of the stem, cell and gene therapy RegMed (SCGT & RM) sector – the advance/decline line scenario of our 43 covered companies.   

  • Opened negative with an A/DL of 17/24 and 2 flats;

 

  • The mid-day slipped neutral  with an A/DL of 20/20 with 3 flats;

 

  • The closing bell stayed negative with A/DL of 20/22 with 1 flat

 

 

Henry’omics:

The SCGT&RM sector opened negative, slipped neutral at the mid-day and closed negative.

  • I am late in publishing having spent most of the afternoon and early evening in the hospital as “my better half” had eye surgery – back again tomorrow!

“Our” universe is on the verge of falling back into “damaged” territory, and I believe investors are not seeing it.

  • Traders are NOT paying attention to valuation but, sentiment and momentum conditions, both of which present serious risks.

The SCGT&RM sector can move up in the face of risks, in fact they often do but, it is based on trading.

  • Right now, I see the inaction as negative.

The iShares Nasdaq Biotechnology ETF (IBB) both closed mildly lower -0.08%.

The Health Care Select Sector SPDR ETF (XLV) is up +0.35% and the iShares Trust - iShares Russell 2000 ETF (IWM) is up +0.74%.

Fibrocell (FCSC)  dropped -36.68% or -$0.73 to $1.26 – after a P2 did NOT meets its endpoints , uniQure (QURE) held second place at -10.48% or -$1.55 to $12.75 – traders were taking the “coins” out of the price,  followed by Adverum (ADVM) <the former Avalanche> who got downgraded by Chardan along with Intrexon (XON) at $26.50 or -$2.12 or -7.41%, also feeling the pain of “scalping” traders..

Who were the winners, StemCells (STEM) which was UP +0.0397 or +9.23% to $0.46 – the must be values in the “remains” – who is kidding whom?  Cesca Therapeutics (KOOL) closed UP +5.65% or +$0.16 to $3.04 – KOOL is “trying” to move the endpoints from AFS to TCPO2 in a CLI trial – I think the “bong” has been passed around too many times with 49.25 K shares trading <3 month average = 226.83 K shares>. Brainstorm (BCLI) closed UP +$0.11 or +4.53% to $2.54 on 31 K shares <3 month average = 51,422>

 

 

Pre-market indications – 4 hit and 0 miss

  • Bellicum Pharma (BLCM) closed FLAT at $13.01 with 234 K shares traded – hit;
  • Capricor (CAPR) closed DOWN -$0.49 – hit;
  • Kite (PHARMA) closed UP +$0.12 – hit;
  • Spark Therapeutics (ONCE) closed DOWN -$0.69 – hit;

 

 

Today’s Bottom Line:

Investors are being forced staying with riskier equities, many just can’t get out!

 

 

Review my fear gauge or the CBOE Volatility Index (VIX):

  • Wednesday traded 14;
  • Tuesday traded near 13.7;
  • Monday traded near 13.5;
  • Friday traded at 13.4;
  • Thursday traded 14.1;
  • Last, Wednesday traded near 14.4;

 

 

Most active sector stocks + and -:

  • Fibrocell (FCSC) -36.68%;
  • Capricor (CAPR) -13.28%;
  • uniQure (QURE) -10.84%;
  • Adverum (ADVM) -7.74%;
  • Intrexon (XON) -7.41%;

Versus …

  • StemCells (STEM) +9.23%;
  • Cesca Therapeutics (KOOL) +5.56%;
  • Brainstorm (BCLI) +4.53%;
  • Stemline (STML) +3.69%;
  • Aduro Biotech (ADRO) +3.43%

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.